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Abstract
Introduction: The status of tumor-infiltrating lymphocytes (TILs) has been recently proposed to predict clinical
outcome of patients with breast cancer. We therefore studied the prognostic significance of CD8+ TILs and FOXP3+
TILs in residual tumors after neoadjuvant chemotherapy (NAC) and the alterations in these parameters before and
after NAC in patients with triple-negative breast cancer (TNBC).
Methods: One hundred thirty-one TNBC patients who received NAC at three institutions were examined. CD8+ TIL
and FOXP3+ TIL in residual tumors and biopsy specimens were evaluated by double-staining
immunohistochemistry. The CD8+ TIL and FOXP3+ TIL status of the residual tumors was assessed, and the rates of
their changes before and after NAC were calculated.
Results: TNBC patients with high CD8+ TIL levels or a high CD8/FOXP3 ratio in residual tumors had significantly
better recurrence-free survival (RFS) and breast cancer-specific survival (BCSS) than patients with low values of these
parameters. In multivariate analyses, CD8+ TIL exhibited strong prognostic significance for RFS, with a hazard ratio (HR)
of 3.09 (95 % confidence interval (CI) 1.537–6.614, P=0.0013). The CD8/FOXP3 ratio was also significantly correlated
with RFS (HR=2.07, 95 % CI 1.029–4.436, P=0.0412). TNBC with larger residual tumor size and positive lymph node
status, which are known prognostic factors, was independently associated with worse RFS (P=0.0064 and P=0.0015,
respectively). High CD8+ TIL levels were a markedly powerful indicator of improved BCSS, with an HR of 3.59 (95 % CI
1.499–9.581, P=0.0036). Nodal status was also associated with BCSS (P=0.0024). TNBC with a high rate of CD8+ TIL
changes was associated with significantly better RFS compared with the low group (P=0.011). Higher rates of
changes in the CD8/FOXP3 ratio were significantly correlated with both better RFS and BCSS compared with
lower rates (P=0.011 and P=0.023, respectively).
Conclusions: This is the first study to demonstrate that high CD8+ TIL and a high CD8/FOXP3 ratio in residual
tumors and increment of these parameters following NAC and accurately predict improved prognosis in TNBC
patients with non-pathological complete response following NAC. These parameters could serve as a surrogate
one for adjuvant treatment in patients with residual disease in the neoadjuvant setting.
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Introduction
Triple-negative breast cancer (TNBC) comprises 10 % to
20 % of breast cancers and is characterized by a lack of
estrogen receptor (ER), progesterone receptor (PgR), and
human epidermal growth factor receptor-2 (HER2) ex-
pression. TNBCs are usually composed of biologically
aggressive and histologically high-grade tumors and tend
to relapse within 3 years of diagnosis with the worst
clinical outcome at this juncture [1–3]. Previous clinical
trials evaluating the efficacy of chemotherapy in the neo-
adjuvant setting revealed that TNBCs are more sensitive
to chemotherapy and have higher rates of pathological
complete response (pCR) than other breast cancer sub-
types [4, 5]. In contrast to patients with pCR and good
clinical outcome, TNBCs with non-pCR have been re-
ported to be associated with a markedly worse prognosis
[4]. Nevertheless, some patients with residual triple-
negative tumors following neoadjuvant chemotherapy
(NAC) are also known to achieve a relatively long-term
survival without recurrence. Therefore, novel biological
markers in residual tumors that can predict the survival
of non-pCR patients and identify those who should re-
ceive new investigational therapeutic agents are required
to further improve the patients with TNBC.
Tumor-infiltrating lymphocytes (TILs) have been re-
ported to be associated with clinical outcome of the
patients in a number of different malignant tumors, in-
cluding breast cancer [6–8]. TILs have been reported to
differ among breast cancer subtypes and are considered
a reliable marker of the efficacy of chemotherapy and
trastuzumab in the TNBC and HER2-enriched subtypes
[9–12]. Dieci et al. recently reported that the presence of
TILs in residual disease following NAC was associated
with improved clinical outcome in TNBCs [13]. The re-
sults of this study could certainly have clinical relevance
for selecting the patients at risk of relapse in TNBCs,
but subclassification of the lymphocytes constituting the
tumor-associated immune system was not performed in
their report. Subclassification of TILs is pivotal; for in-
stance, cytotoxic T cells (CD8+ T cells) have been re-
ported to be associated with improved clinical outcomes
in patients with breast cancer [14–16], but other studies
could not confirm this association [17]. In addition,
regulatory T cells defined as forkhead box protein 3
(FOXP3)+ T cells play a pivotal role in suppressing anti-
tumor immunity [18, 19]. However, it is also true that
the prognostic roles of FOXP3 remain controversial; for
instance, breast cancers with FOXP3+ TIL have been
reported to be less sensitive to cytotoxic chemother-
apy and have a worse prognosis [17, 20], but others
reported that those with FOXP3+ TIL have a better
prognosis [21, 22].
The results of recent preclinical studies revealed that
cytotoxic agents could possibly exert their antitumor
activities by inducing an immune response against tumor
cells [23, 24]. In a small breast cancer series of 21 patients
with residual disease following NAC, chemotherapy-
induced lymphocytes in the tumor bed were observed in
seven patients [25]. The study of TNBCs by Dieci et al.
above also reported that TILs were lower in pre- than
post-chemotherapy specimens in 18 of 19 patients [13].
Ladoire et al. analyzed the changes in subclassified TILs,
focusing upon CD8 and FOXP3 status in a breast cancer
series including 19 cases of ER-negative disease, and re-
ported that the ratio of CD8/FOXP3 following chemother-
apy may correlate with improved prognosis [26]. However,
more than half of the NAC regimens administered to pa-
tients in previous studies were anthracycline-based regi-
mens, whereas the current standard is anthracycline- and
taxane-based regimens. In patients with TNBC, the associ-
ation of CD8+ TIL and FOXP3+ TIL status in residual
tumors and changes induced by anthracycline- and
taxane-based chemotherapy with prognosis has there-
fore remained unknown.
Here, in this study, we evaluated the prognostic signifi-
cance of CD8+ TIL and FOXP3+ TIL in residual tumors
following NAC comprising anthracyclines and taxanes
and the changes of CD8+ TIL and FOXP3+ TIL before
and after the therapy in a relatively larger TNBC cohort
than those of previous studies. The aim of our study was
to identify a reliable marker for more appropriate selec-
tion of high-risk patients eligible for more aggressive
therapeutic agents, including novel investigational ones
in development in patients with TNBC.
Methods
Cohort and sample selection
In this retrospective study, we used data for 131 con-
secutive TNBC patients who received NAC and surgery
at three institutions (Tohoku University Hospital, Sen-
dai, Japan; Tohoku Kosai Hospital, Sendai, Japan; and
Nahanishi Clinic, Okinawa, Japan) between 2007 and
2012. All biopsy specimens prior to NAC and surgical
specimens were fixed in 10 % neutral buffered formalin
and embedded in paraffin. The three institutional review
boards, Ethics Committee of Tohoku University Gradu-
ate School of Medicine, Institutional Review Board of
Tohoku Kosai Hospital, and Institutional Review Board
of Nahanishi Clinic, approved the protocol of this study,
which was conducted in accordance with the
Declaration of Helsinki. Written informed consent was
obtained from all patients.
Double-staining immunohistochemistry and scoring of
CD8 and FOXP3
The formalin-fixed paraffin-embedded specimens were
cut into 4-μm-thick sections and placed on glue-coated
glass slides for immunohistochemistry (IHC). Briefly, the
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specimens were deparaffinized in xylene and hydrated in
graded alcohols and distilled water. Endogenous perox-
idase activity was blocked with 3 % hydrogen peroxidase
for 10 min. FOXP3 antigen retrieval was performed
by autoclaving (Tomy SX-500 High-Pressure Steam
Sterilizer, Tomy Seiko Co., Ltd., Tokyo, Japan) in citrate
buffer (pH 6.0) and heating at 121 °C for 5 min. The sam-
ples were then incubated for 30 min at room temperature
(RT) in a blocking solution with 1 % rabbit serum
(Nichirei Bioscience, Tokyo, Japan). Then, the anti-FOXP3
antibody reaction (clone 236A/E7; Abcam, Tokyo, Japan)
was performed at a dilution of 1:100 for 16 h at 4 °C. A
secondary antibody reaction was performed by using
a biotinylated rabbit anti-mouse antibody (Nichirei
Bioscience) for 30 min at RT. Peroxidase-conjugated
streptavidin (Nichirei Bioscience) was subsequently
used for 30 min at RT, and DAB was used to
visualize the binding of the first antibody. Next, CD8
antigen retrieval was performed by autoclaving in
citrate buffer (pH 7.0); the sample was then heated
at 121 °C for 5 min and incubated for 30 min at RT
in a blocking solution of 1 % rabbit serum. The
anti-CD8 antibody reaction (clone C8/144B; Nichirei,
Tokyo, Japan) was performed at a dilution of 1:40 for 16 h
at 4 °C. After the biotin-streptavidin reaction, Vector Blue®
was used to visualize the binding of the anti-CD8 antibody
(blue), in contrast to FOXP3 (brown) [27].
The assessment of unstained TILs in our study was
based on the recommendation by an International TIL
Working Group [8]. TILs were evaluated within the
stromal compartment close to the invasive tumor,
and the percentage of stromal TILs was reported. To
evaluate the tumor infiltration of CD8+ and FOXP3+
lymphocytes, we performed the experiment, whose pro-
cedures were as follows: firstly, four non-overlapping
stromal fields with abundant TILs within the borders of
the invasive tumor on low-power hematoxylin-eosin-
stained field (40×) were selected in both full sections of
biopsy specimens and the entire tumor bed of surgical
specimens for each case. Then, in the same fields of
double staining with CD8 and FOXP3 as the above four
fields, the number of CD8+ or FOXP3+ lymphocytes
was counted under high-power magnification (400×)
[14, 20]. Finally, the mean number of CD8+ or FOXP3+
lymphocytes per field was counted, and the ratio of CD8+
to FOXP3+ lymphocytes was calculated for each tumor.
One hundred one surgical specimens and 78 biopsy speci-
mens were scored twice by the same pathologist in order
to confirm the reproducibility of the CD8 and FOXP3
scoring. The results indicated that high correlation rates
were observed by Pearson correlation analysis (r=0.94–
0.96). After that, we assessed the interpersonal reproduci-
bility of the scoring by two blinded pathologists, and high
correlation coefficients were obtained (r=0.75–0.88).
Evaluation of ER, PgR, HER2, Ki-67, EGFR, and CK5/6
The ER and PgR statuses were evaluated by immuno-
staining using monoclonal antibodies (clone 107925
and 102333, respectively; Roche Diagnostics, Basel,
Switzerland); nuclear staining of greater than 1 % was
considered positive. HER2 status was evaluated by IHC
(HercepTest, code K5204; Dako, Glostrup, Denmark) or
by fluorescence in situ hybridization (FISH) and was cal-
culated as the gene copy ratio of HER2 to CEP17 (the
PathVysion HER2 DNA Probe Kit; Abbott, Chicago, IL,
USA). HER2 positivity was defined as 3+ receptor over-
expression by IHC or as a HER2-to-CEP17 ratio of at
least 2.2 by FISH or as both, in accordance with the
American Society of Clinical Oncology/College of
American Pathologists guidelines [28].
We performed IHC for Ki-67, EGFR, and CK5/6.
The Ki-67 labeling index was determined with an
anti-MIB-1 monoclonal antibody (code M7240; Dako)
by counting 1000 tumor cells in the hot spots [29, 30].
EGFR was interpreted as positive if the membranes
of 10 % or more carcinoma cells were stained by
using representative monoclonal antibodies (code
K1492; Dako). CK5/6 was interpreted as positive if
10 % or more carcinoma cells displayed monoclonal
antibody binding (code M7237; Dako) in the cyto-
plasm [31, 32]. The basal-like type was defined as
tumors expressing either EGFR or CK5/6, which are
specific basal markers. Two pathologists performed
all pathological diagnoses and staining assessments of
individual cases.
Clinical information, pathological response, and survival
Clinical information for individual TNBC cases was ob-
tained from the databases of the three institutions and
was reviewed. The pathological therapeutic response was
evaluated at the surgically resected tumor after NAC.
The surgical specimens were cut into 5-mm slices and
processed with hematoxylin-eosin staining. pCR was
defined as the absence of all invasive cancer cells
and lymph node metastasis, regardless of the pres-
ence or absence of noninvasive cancer cells. We set
two survival end points: (i) recurrence-free survival
(RFS) was defined as the time from surgery until the
date of disease recurrence, and (ii) breast cancer-
specific survival (BCSS) was defined as the time until
death due to breast cancer.
Statistical analyses
All statistical analyses were performed by using SAS
software, JMP Pro 11 (JMP, Tokyo, Japan). The Kaplan-
Meier method and the log-rank test were used to com-
pare the RFS and BCSS curves between groups. Hazard
ratios (HRs) and 95 % confidence intervals (CIs) of the
variables were calculated by using the Cox proportional
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hazard regression model. A multivariate Cox regression
analysis including all of potential variables that were sig-
nificantly associated with survival in each univariate ana-
lysis was performed. We examined the prognostic
significances of TIL-related variables as both a continu-
ous and a categorical variable. Associations among vari-
ables were evaluated by using Fisher’s exact test or the
chi-squared test. The Mann-Whitney U and Spearman’s
correlation tests were used to compare non-continuous
parameters. All tests were two sided, and a P value of
less than 0.05 was considered significant.
Results
Clinicopathological characteristics and their association
with CD8+ and FOXP3+ TIL
Of the 131 patients with TNBC, 110 (84 %) received
NAC containing both anthracyclines and taxanes as
current standard regimens. Nineteen patients received
anthracycline-based regimens for NAC, and the great
majority received taxane-based regimens as adjuvant
therapy after surgery. Thirty patients (30/131; 22.9 %)
were diagnosed as having pCR according to the detailed
pathological examination.
Immunohistochemical analyses of CD8, FOXP3, EGFR,
CK5/6, and Ki-67 and the CD8+/FOXP3+ ratio by the
double-staining method were subsequently performed in
residual tumors from 101 patients with TNBC treated
with NAC, and representative images are shown in
Fig. 1. The characteristics of the 101 evaluable TNBC
patients with respect to CD8 and FOXP3 status and
the CD8/FOXP3 ratio are presented in Table 1. A
total of 85 of these patients (84 %) received anthracy-
cline- and taxane-based neoadjuvant regimens, and
most of the others received anthracycline-based neo-
adjuvant regimens and taxane-based regimens after
surgery. The cutoffs for high or low infiltration were
defined as near the median number of infiltrating
cells per field as follows: CD8, 100 infiltrating cells
per field; FOXP3, 60 infiltrating cells per field; and
CD8/FOXP3 ratio, 1.6. There was no difference in
CD8+ TIL and FOXP3+ TIL status and CD8/FOXP3
ratio among the NAC regimens. TNBC patients with
small residual tumor size (≤2 cm) after NAC com-
prised 59/101 (58 %) and had significantly higher
CD8+ TIL levels than patients with residual tumors
larger than 2 cm (P=0.005). There was no association
between residual tumor size and FOXP3+ TIL or the
CD8/FOXP3 ratio. Residual tumors with higher histo-
logical grades and higher Ki-67 with a cutoff of 50 %
near the median value tended to have lower CD8/FOXP3
ratios, but this trend was not significant (P=0.068 and
0.056, respectively). Significant positive correlations were
detected among CD8+ TIL, FOXP3+ TIL, and CD8/FOXP3
ratio (CD8+ versus FOXP3+: P=0.0003, CD8+ versus CD8/
FOXP3 ratio: P=0.010, FOXP3+ versus CD8/FOXP3 ratio:
P=0.0001). No correlation of other factors, age, nodal status
Fig. 1 Immunohistochemical double staining of tumor-infiltrating CD8+ (blue) and FOXP3+ (brown) lymphocytes. The representative tumor tissue
of high (a) and low (b) infiltration of lymphocytes on surgical specimens after neoadjuvant chemotherapy (black arrow points to CD8+ lymphocytes, and
red arrow points to FOXP3+ lymphocytes)
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after NAC, and basal-like type with high or low CD8+ TIL,
FOXP3+ TIL, and CD8/FOXP3 ratio was observed.
We also assessed residual cancer burden (RCB)
scores on surgical specimens of non-pCR patients by
using the Web-based MD Anderson RCB calculator
and its relationship with CD8+ TIL, FOXP3+ TIL,
and CD8/FOXP3 ratio [33]. The weak inverse rela-
tions were detected between RCB scores and CD8+
TIL or CD8/FOXP3 ratio (Additional file 1A, C), but
this trend was not observed between RCB scores and
FOXP3+ TIL (Additional file 1B). From the evalu-
ation of RCB categories, significant correlations were
Table 1 Clinicopathological factors of triple-negative breast tumors with the status of CD8, FOXP3, the ratio of CD8/FOXP3 (N=101)
Factors CD8 FOXP3 CD8/FOXP3
High Low P value High Low P value High Low P value
Age, years 0.838 0.415 0.682
<50 22 17 22 17 16 23
>50 33 29 29 33 29 33
Residual tumor size 0.005* 0.373 0.487
<2.0 cm 39 20 32 27 28 31
>2.0 cm 16 26 19 23 17 25
Nodal status after NAC 0.167 0.491 0.094
Negative 35 23 31 27 30 28
Positive 20 23 20 23 15 28
Residual cancer burden 0.052 0.908 0.013*
Class I 5 2 3 4 6 1
Class II 41 27 35 33 32 36
Class III 9 17 13 13 7 19
Histological grade 0.602 0.329 0.068
I, II 21 16 15 22 22 17
III 34 30 36 28 23 39
Neoadjuvant chemotherapy 0.726 0.319 0.136
Anthracycline and taxane-based 45 40 43 42 39 46
Anthracycline-based 9 5 8 6 4 10
Other 1 1 0 2 2 0
Basal-like type 0.314 0.546 0.417
Basal-like 30 30 32 28 29 31
Non basal-like 25 16 19 22 16 25
Ki-67 LI (cutoff: 50) 0.551 0.322 0.056
Low 26 25 23 28 28 23
High 29 21 28 22 17 33
CD8 (cutoff: 100) 0.0003* 0.010*
Low 14 32 14 32
High 37 18 31 24
FOXP3 (cutoff: 60) 0.0003* 0.0001*
Low 18 32 32 18
High 37 14 13 38
CD8/FOXP3 (cutoff: 1.6) 0.010* 0.0001*
Low 24 32 38 18
High 31 14 13 32
NAC neoadjuvant chemotherapy, LI labeling index
*The P value is significant
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detected between RCB classes and CD8/FOXP3 ratio
(P=0.013, Table 1).
Association of CD8+ TIL, FOXP3+ TIL, and clinicopathological
factors with prognosis
The median follow-up time was 3.6 years. TNBCs
classified into the high CD8+ TIL group for residual
tumors had significantly better RFS and BCSS than
the low CD8+ TIL group as determined by the Kaplan-
Meier method and the log-rank test (P<0.0001, both end
points). The 5-year RFS rates were 73 % for the high
CD8+ TIL group and 30 % for the low CD8+ TIL
group, and the 5-year BCSS rates were 86 % for the
high CD8+ TIL group and 42 % for the low CD8+ TIL
group (Fig. 2a, b). A higher CD8/FOXP3 ratio was also sig-
nificantly correlated with both better RFS and BCSS com-
pared with a lower CD8/FOXP3 ratio (P=0.009 and
P=0.027, respectively). The 5-year RFS rates were 72 % and
40 % in patients with high and low CD8/FOXP3 ratios, re-
spectively, and the 5-year BCSS rates were 77 % and 56 %
in patients with high and low CD8/FOXP3 ratios, respect-
ively (Fig. 2e, f). By contrast, no association between the
status of FOXP3+ TIL and RFS or BCSS was observed
(P=0.417 and P=0.175, respectively; Fig. 2c, d).
Patients with 2 cm or smaller residual tumors had a
significantly better prognosis than those with residual
tumors larger than 2 cm (RFS, P <0.0001; BCSS,
P=0.005; Additional file 2A, B). No residual axillary
lymph node disease after NAC was significantly associ-
ated with improved RFS and BCSS compared with re-
sidual lymph node metastases (P <0.0001, both end
points; Additional file 2C, D). Although patients with a
basal-like type who did not achieve pCR had a worse
RFS than those with a non-basal-like type (defined as
not expressing EGFR or CK5/6; P=0.042), the BCSS
curve did not differ between these types (P=0.269;
Additional file 3A, B). There was no correlation between
the two survival end points and Ki-67 status (RFS,
P=0.349; BCSS, P=0.132; Additional file 3C, D) or the
other clinicopathological factors: age, histological grade,
and type of NAC regimen.
Additionally, we evaluated the status of unstained TILs
according to the recommendation by an International
TIL Working Group 2014 [8]. The patients classified
into the high TIL group with the recommended cutoff of
60 % underwent the significantly better clinical course
compared with those with low TILs regarding RFS
(P=0.046; Additional file 4A). On the other hand, the
Fig. 2 Recurrence-free survival (RFS) and breast cancer-specific survival (BCSS) in patients with different status of CD8+ tumor-infiltrating lymphocyte (TIL),
FOXP3+ TIL, and CD8/FOXP3 ratio. Estimated Kaplan-Meier curves of RFS (a) and BCSS (b) in patients with high or low CD8+ TIL, those of
RFS (c) and BCSS (d) in patients with high or low FOXP3+ TIL, and those of RFS (e) and BCSS (f) in patients with high or low CD8/FOXP3
ratio. pCR pathological complete response
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BCSS curves were not statistically different between high
and low TIL groups (Additional file 4B). The shorter
follow-up time probably influenced the discordant re-
sults between RFS and BCSS.
Prognostic value of CD8+ and FOXP3+ TIL on residual
tumor in univariate and multivariate analysis
Both univariate and multivariate analyses were per-
formed to determine the association between prognosis
and variables, including clinicopathological factors, CD8,
FOXP3, the CD8/FOXP3 ratio, unstained TILs, basal-
like status, and Ki-67. As reported in Table 2, CD8+ TIL,
the CD8/FOXP3 ratio, unstained TILs, residual tumor
size, nodal status after NAC, and basal-like type were
significantly correlated with RFS in univariate analyses.
We investigated these variables for their independent as-
sociation with RFS by using a multivariate Cox regres-
sion model. The results did reveal that CD8+ TIL had
strong prognostic significance for RFS with HRs of 1.01
(95 % CI 1.001–1.011, P=0.0249) as a continuous vari-
able (per 1 point increase) and 3.09 (95 % CI 1.537–
6.614, P=0.0013) as a categorical variable. The CD8/
FOXP3 ratio as a categorical variable was also signifi-
cantly correlated with RFS (HR=2.07, 95 % CI 1.029–
4.436, P=0.0412), and that was suggestively associated
with RFS as a continuous variable (HR=1.14 per 1 point
increase, 95 % CI 0.994–1.381, P=0.0631). TNBC pa-
tients with larger residual tumor size and positive lymph
node status, known prognostic factors, independently
exhibited worse RFS (HR=2.59, 95 % CI 1.302–5.396,
P=0.0064; HR=2.97, 95 % CI 1.509–6.178, P=0.0015,
respectively). With regard to BCSS, CD8+ TIL, the CD8/
FOXP3 ratio, residual tumor size, and nodal status after
NAC were significantly correlated with survival in the
univariate analyses (Table 3). No difference in the BCSS
end point was detected for basal-like type and non-
basal-like type tumors. In multivariate analyses, the re-
sults indicated that a high number of CD8+ TILs was a
markedly powerful indicator of improved BCSS, with
HRs of 1.01 (95 % CI 1.001–1.015, P=0.0152) as a con-
tinuous variable (per 1 point increase) and 3.59 (95 % CI
1.499–9.581, P=0.0036) as a categorical variable. Nodal
status after NAC was also significantly associated with
BCSS (HR=3.76, 95 % CI 1.574–10.02, P=0.0024;
Table 3).
Changes of CD8+ and FOXP3+ TIL between before and
after NAC and their association with prognosis
We investigated the status of CD8+ TIL and FOXP3+
TIL and the CD8/FOXP3 ratio in the core biopsy speci-
mens and calculated the rates of changes before and
after NAC. Pre-treatment biopsy specimens were avail-
able for 78 of the 101 included TNBCs. CD8+ TIL levels
increased after NAC in 54 of 78 patients (69 %), and the
change rates varied from 0.03 to 20.08 (the ratio of post-
treatment CD8+ TIL to pre-treatment CD8+ TIL) (Figs. 3
and 4). FOXP3+ TIL increased in 35 of 78 patients
(45 %), and the change rates varied from 0.02 to
11.00 (the ratio of post-treatment FOXP3+ TIL to pre-
treatment FOXP3+ TIL). In 37 of 78 patients (47 %), the
Table 2 Univariate and multivariate analyses of variables associated with RFS in TNBC (N=101)
Variables Univariate analysis Multivariate analysis
HR 95 % CI P value HR 95 % CI P value
Age (<50 vs. >50) 1.45 0.765–2.727 0.2488
Residual tumor size (>2.0 cm vs. <2.0 cm) 3.92 2.045–7.902 <0.0001* 2.59 1.302–5.396 0.0064*
Nodal status after NAC (positive vs. negative) 3.84 2.003–7.732 <0.0001* 2.97 1.509–6.178 0.0015*
Grade (III vs. I, II) 1.01 0.352–4.234 0.9903
Basal-like vs. non basal-like 2.03 1.035–4.267 0.0389* 2.01 0.979–4.262 0.0532
Ki-67 LI (high vs. low) 1.35 0.716–2.562 0.3526
Unstained TILs (low vs. high) 3.63 1.110–22.34 0.0301* 2.01 0.572–12.71 0.3101
CD8 (low vs. high) 3.92 2.016–8.105 <0.0001* 3.09 1.537–6.614 0.0013*
CD8 (as a continuous variable)a 1.01b 1.002–1.012 0.0021* 1.01b 1.001–1.011 0.0249*
FOXP3 (low vs. high) 1.30 0.689–2.456 0.4199
FOXP3 (as a continuous variable)a 1.00b 0.997–1.008 0.3753
CD8/FOXP3 (low vs. high) 2.43 1.239–5.097 0.0090* 2.07 1.029–4.436 0.0412*
CD8/FOXP3 (as a continuous variable)a 1.28b 1.085–1.616 0.0011* 1.14b 0.994–1.381 0.0631
Multivariate cox regression analyses were performed for all potential variables that were significantly associated with survival in univariate analysis
RFS recurrence free survival, HR hazard ratio, CI confidence interval, NAC neoadjuvant chemotherapy, LI labeling index, TIL tumor-infiltrating lymphocyte
*The P value is significant
aAnalyses were performed by the continuous variables
bThe HRs of the continuous variables are shown as a unit ratio
Miyashita et al. Breast Cancer Research  (2015) 17:124 Page 7 of 13
Table 3 Univariate and multivariate analyses of variables associated with BCSS in TNBC (N=101)
Variables Univariate analysis Multivariate analysis
HR 95 % CI P value HR 95 % CI P value
Age (<50 vs. 50<) 1.85 0.877–3.944 0.1055
Residual tumor size (>2.0 cm vs. <2.0 cm) 2.89 1.354–6.520 0.0059* 1.37 0.593–3.332 0.4637
Nodal status after NAC (positive vs. negative) 4.83 2.144–12.29 <0.0001* 3.76 1.574–10.02 0.0024*
Grade (III vs. I, II) 1.45 0.460–2.173 0.4014
Basal-like vs. non basal-like 1.56 0.721–3.635 0.2634
Ki-67 LI (high vs. low) 1.78 0.839–3.935 0.1329
Unstained TILs (low vs. high) 2.38 0.709–14.77 0.1815
CD8 (low vs. high) 4.75 2.106–12.12 0.0001* 3.59 1.499–9.581 0.0036*
CD8 (as a continuous variable)a 1.01b 1.004–1.016 0.0007* 1.01b 1.001–1.015 0.0152*
FOXP3 (low vs. high) 1.68 0.795–3.699 0.1751
FOXP3 (as a continuous variable)a 1.00b 0.998–1.013 0.1412
CD8/FOXP3 (low vs. high) 2.53 1.128–6.436 0.0233* 1.28 0.526–3.453 0.5932
CD8/FOXP3 (as a continuous variable)a 1.25b 1.048–1.649 0.0077* 1.11b 0.953–1.397 0.2115
Multivariate cox regression analyses were performed for all potential variables that were significantly associated with survival in univariate analysis
BCSS breast cancer-specific survival, HR hazard ratio, CI confidence interval, NAC neoadjuvant chemotherapy, LI labeling index, TIL tumor-infiltrating lymphocyte
*The P value is significant
aAnalyses were performed by the continuous variables
bThe HRs of the continuous variables are shown as a unit ratio
Fig. 3 The cases with high change rates of CD8+ TIL and CD8/FOXP3 ratio before and after neoadjuvant chemotherapy (NAC). The cutoffs of a
high or low rate of changes were defined as near the median ratio as follows: CD8+ TIL, 1.4 and CD8/FOXP3 ratio, 1.8. Immunohistochemical
images of tumor-infiltrating CD8+ (blue) and FOXP3+ (brown) lymphocytes in pretreatment biopsy specimens (a) and residual tumors after NAC
(b) of the same patient (black arrow points to CD8+ lymphocytes, and red arrow points to FOXP3+ lymphocytes). c Changing levels of CD8+ TIL in
each case; 9 of 38 cases experienced cancer recurrence, and 7 patients died. d Changing levels of CD8/FOXP3 ratio in each case; 8 of 37 cases
experienced cancer recurrence, and 5 patients died
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CD8/FOXP3 ratio increased, and the change rates
varied from 0.12 to 18.32 (the ratio of post-treatment
CD8/FOXP3 ratio to pre-treatment CD8/FOXP3 ratio)
(Figs. 3 and 4).
In 38 patients with a high rate of changes in CD8+
TILs, nine cases experienced cancer recurrence. Of the
38 patients, 25 cases were classified into the high-
change group of CD8/FOXP3 ratio and 13 cases were
classified into the low-change group. There were 5/25
(20 %) and 4/13 (31 %) cases with recurrence in the
high- and low-change groups of CD8/FOXP3 ratio, re-
spectively. The recurrence rates of the two groups were
not statistically different (P=0.4645). Twenty of 40 pa-
tients with a low rate of changes in CD8+ TILs experi-
enced cancer recurrence. In 28 patients with a low rate
of changes in both CD8+ TILs and CD8/FOXP3 ratio,
17/28 (61 %) cases underwent recurrence which was sig-
nificantly higher than that of patients with a high rate of
changes in CD8/FOXP3 ratio, 3/12 (25 %) (P=0.0352).
We investigated survival with regard to the different
change rates of CD8+ TIL and FOXP3+ TIL status
and the CD8/FOXP3 ratio by using the Kaplan-Meier
method and log-rank test. The cutoffs of high or low
rate of changes were defined as near the median ratio
of post-treatment value to pre-treatment value in our
TNBC cohort as follows: CD8, 1.4; FOXP3, 1.0; and
CD8/FOXP3, 1.8. TNBCs classified into the high rate
of change in CD8+ TIL group had a significantly better
RFS than those with a low rate of change (P=0.011), and
BCSS was suggestively better in the high rate of change in
the CD8+ TIL group compared with the low-rate group
(P=0.064). The 5-year RFS rates were 74 % for the high
rate of change in CD8+ TIL group and 20 % for the low-
rate group, and the 5-year BCSS rates were 81 % for the
high rate of change in CD8+ TIL group and 52 % for the
low-rate group (Fig. 5a, b). The patients with higher
change of the CD8/FOXP3 ratio had significantly better
RFS and BCSS compared with those not (P=0.011 and
P=0.023, respectively). The 5-year RFS rates were 68 %
and 41 % in patients with high and low rates of
changes in the CD8/FOXP3 ratio, and the 5-year
BCSS rates were 78 % and 58 % in patients with high
and low rates of changes in the CD8/FOXP3 ratio,
respectively (Fig. 5e, f ). However, no significant correl-
ation was detected between the degrees of FOXP3+
TIL change and RFS or BCSS (P=0.581 and P=0.999,
respectively; Fig. 5c, d).
Discussion
Our study is the first to evaluate CD8+ TIL, FOXP3+
TIL, and the CD8/FOXP3 ratio in residual tumors and
changes in these parameters after chemotherapy in more
than 100 patients with TNBC. The results indicated that
a high CD8+ TIL and the high CD8/FOXP3 ratio in
Fig. 4 The cases with low change rates of CD8+ TIL and CD8/FOXP3 ratio before and after neoadjuvant chemotherapy (NAC). The cutoffs of a
high or low rate of changes were defined as near the median ratio as follows: CD8+ TIL, 1.4 and CD8/FOXP3 ratio, 1.8. Immunohistochemical
images of tumor-infiltrating CD8+ (blue) and FOXP3+ (brown) lymphocytes in pretreatment biopsy specimens (a) and residual tumors after NAC
(b) of the same patient (black arrow points to CD8+ lymphocytes, and red arrow points to FOXP3+ lymphocytes). c Changing levels of CD8+ TIL in
each case; 20 of 40 cases experienced cancer recurrence and 14 patients died. d Changing levels of CD8/FOXP3 ratio in each case; 21 of 41 cases
experienced cancer recurrence, and 16 patients died
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residual tumors and increases in these parameters after
NAC compared with pretreatment status in biopsy sam-
ples can accurately predict improved RFS and BCSS in
TNBC patients with non-pCR following NAC.
A recent meta-analysis of studies exploring the prog-
nostic value of TILs in patients with TNBC revealed that
high TIL levels were significantly associated with better
survival outcome in TNBCs, and the authors concluded
that TIL status should be considered a strong prognostic
factor in this subtype [10]. Dieci et al. also reported the
importance of TIL in residual disease after NAC in the
largest cohort of 278 patients with TNBC, and their re-
sults have had a large impact in both preclinical and
clinical practice [13]. Focusing on the subsets of TIL, the
tumor-related immune system has two paradoxically
functional components: cytotoxic CD8+ T cells and regu-
latory FOXP3+ T cells. Cytotoxic T cells recognize
foreign antigens on tumor cells through specific interac-
tions with T-cell receptors, which lead to tumor cell
death by inducing the release of proteins such as per-
forin and granzyme from activated T cells [34–36]. By
contrast, FOXP3+ TILs, which diminish the immune
response to self-antigens, have a critical role in sup-
pressing anti-tumor immunity [18, 19]. Therefore,
the evaluation of these two major components of the
tumor-related immune system is required for the as-
sessment of chemotherapeutic efficacy in patients
with breast cancer.
Based on the limited data on the detailed subclassifica-
tion of TILs as CD8+ TIL or FOXP3+ TIL or not in
TNBCs, studies evaluating the association of CD8+ TIL
or FOXP3+ TIL status with clinical outcome have re-
ported conflicting findings [14–17, 20–22, 26, 27]. In
the above-mentioned meta-analysis, the absence of
CD8+ TIL was reported to be associated with worse
disease-free survival and overall survival (HR=0.24,
95 % CI 0.12–0.45, P <0.0001, HR=0.58, 95 % CI
0.52–0.65, P <0.0001, respectively), and the absence
of FOXP3+ TIL+ also correlated with worse disease-
free survival and overall survival (HR=0.44, 95 % CI
0.27–0.72, P=0.001, HR=0.76, 95 % CI 0.60–0.96,
P=0.019, respectively) [10]. This pooled estimation
focusing on CD8+ TIL and FOXP3 TIL+ was consid-
ered valuable, but the results should be interpreted
carefully because studies of the value of TIL in the
neoadjuvant setting were excluded from this meta-
analysis. Therefore, our present retrospective study of
the status of CD8+ TIL and FOXP3+ TIL in residual
tumors after NAC could provide results directly con-
nected to present clinical practices, in which NAC is
Fig. 5 Recurrence-free survival (RFS) and breast cancer-specific survival (BCSS) in patients with different change rates of CD8+ tumor-infiltrating
lymphocyte (TIL), FOXP3+ TIL, and CD8/FOXP3 ratio. Estimated Kaplan-Meier curves of RFS (a) and BCSS (b) in patients with high or low change
rates of CD8+ TIL before and after neoadjuvant chemotherapy, those of RFS (c) and BCSS (d) in patients with high or low change rates of FOXP3+ TIL,
and those of RFS (e) and BCSS (f) in patients with high or low change rates of CD8/FOXP3 ratio
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the major treatment mode for patients with TNBC. The
positive correlation between high CD8+ TIL in residual
tumors after NAC and improved prognosis identified in
this study is consistent with several previous studies in-
vestigating the value of CD8+ TILs in the adjuvant setting
for TNBCs [14–16]. In addition, the importance of the
CD8/FOXP3 ratio following chemotherapy in our TNBC
cohorts supports the results of a unique small study that
suggested that the ratio of CD8/FOXP3 after chemother-
apy is correlated with prognosis [26].
The additional prognostic value of stained TILs, CD8+
TILs, FOXP3+ TILs, and CD8/FOXP3 ratio should be
discussed because there have been several studies which
find the significance of unstained TILs in patients with
TNBC [8, 10–13]. In our cohort, the positive correlation
was observed between the status of unstained TILs and
CD8+ TILs (R=0.432, P <0.001). This is thought to be
the statistical reason that unstained TILs were not sig-
nificant in our multivariate analysis; on the contrary,
CD8+ TILs were significant. Based on the results, stain-
ing CD8 enabled us to identify the patients with poor
prognosis more effectively than the unstained TILs
which could be more available than stained TILs in
clinical practices.
The results of preclinical studies indicate that the de-
mise of immunogenic cells induced by cytotoxic agents
could enable the cross-presentation of antigens, den-
dritic cell activation, and the induction of tumor-specific
cytotoxic T cells labeled by CD8, a major component of
the tumor-related immune system [23, 24]. To further
clarify the dynamic change in tumor infiltration by lym-
phocytes in patient samples, the changes in CD8+ TIL
and FOXP3+ TIL caused by chemotherapy compared
with baseline in biopsy specimens were determined for
the first time in this study. We focused on the changes
in CD8+ TIL, FOXP3+ TIL, and the CD8/FOXP3 ratio
induced by anthracycline- and taxane-based NAC in a
cohort of 78 patients with TNBC. Our study demon-
strated that increases in CD8+ TIL and the CD8/FOXP3
ratio were significantly associated with improved clinical
outcomes. These results suggest that activation of the
activated tumor-related immune system by cytotoxic
agents might affect the micro-metastatic tumor cells in
the bone marrow or blood vessels or other parts of
the body, a hypothesis that certainly merits further
investigation.
The present study indicates that the post-chemotherapy
status of CD8+ TIL and the CD8/FOXP3 ratio and the
changes in these parameters caused by chemotherapy
could be used to identify a subgroup of patients eligible
for clinical trials of investigational drugs. Recently, a novel
approach targeting programmed death 1 (PD-1) and the
PD-1 ligand (PD-L1) pathway has been investigated in hu-
man patients with breast cancer [37, 38]. PD-1 is a
member of the CD28/cytotoxic T-lymphocyte antigen 4
(CTLA-4) family of co-stimulatory receptors and is a
negative regulator of T-cell lymphocytes [39, 40]. The PD-
1 ligand PD-L1 is expressed on various tumor cells,
including breast cancer cells [38]. Early-phase clinical
trials using anti-PD-1 and PD-L1 antibodies have demon-
strated favorable objective responses in patients with non-
small cell lung cancer, malignant melanoma, and renal cell
carcinoma [41–43]. For breast cancer, a phase II trial of an
anti-PD-1 antibody will soon be initiated on the basis of
the results of a phase I trial that demonstrated durable ef-
ficacy and acceptable safety in patients with heavily treated
TNBC (the results of the study were presented at the 37th
San Antonio Breast Cancer Symposium but have not yet
been published). However, the association between the
presence of CD8+ TIL, FOXP3+ TIL, PD-1, PD-L1, and
the therapeutic efficacy of an anti-PD-1 antibody or PD-
L1 antibody has not been examined. Further studies may
be required for patient stratification for the development
of these drugs.
As a potential limitation of our study, the status of
TILs on biopsy specimens may not reflect that of the en-
tire tumor before chemotherapy because of the tumor
heterogeneity. By carefully estimating all pieces (four or
more) of biopsy specimens, we minimized the limitation
which was common among the studies with neoadjuvant
settings. Further studies are needed to validate the re-
sults of the present study.
Conclusions
This is the first study to demonstrate that high CD8+
TIL levels and CD8/FOXP3 ratio in residual tumors
could accurately predict the better clinical outcome
in TNBC patients with non-pCR following NAC and
that the changes of these parameters in breast cancer
tissues following NAC were also significantly associ-
ated with eventual clinical outcome in TNBCs. These
parameters could be a surrogate for adjuvant treat-
ment in patients with residual disease in the neoad-
juvant setting.
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Additional file 1: The correlation diagrams of CD8+ TIL, FOXP3+ TIL,
and CD8/FOXP3 ratio with residual cancer burden (RCB) score of
each tumor. The weak inverse relations were detected between RCB
scores and CD8+ TIL (A) or CD8/FOXP3 ratio (C), but this trend was not
observed between RCB scores and FOXP3+ TIL (B). FOXP3 forkhead box
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